Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
- Subjects must have histologically confirmed diagnosis of multiple myeloma
- Subjects must have measurable disease, as defined by at least one of the following: * Serum monoclonal protein M-protein level >= 0.5 g/dL * Urinary M-protein excretion of >= 200 mg over a 24-hour period * Involved free light chain level >= 10 mg/dL, along with an abnormal free light chain ratio
- Subjects must have disease that has relapsed and/or refractory after their most recent therapy, with progressive disease (PD) being defined as an increase of 25% from the lowest response value in any one or more of the following: * Serum M-component protein (the absolute increase must be >= 0.5 g/dL) and/or * Urine M-component protein (the absolute increase must be >= 200 mg/24 hours) and/or * Only in subjects without a measurable serum and urine M protein level: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase) must be > 10 mg/dL * Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas * Development of hypercalcemia (corrected serum calcium > 11.5 mg/dL) that can be attributed solely to the plasma cell proliferative disorder
- Subjects with one to three lines of therapy for their disease with a prior therapy is defined as 2 or more cycles of therapy given as a treatment plan for multiple myeloma (MM) (e.g. a single-agent or combination therapy or a sequence of planned treatments such as induction therapy followed by autologous stem cell transplant (SCT) and then consolidation and/or maintenance therapy)
- Subjects must have achieved a partial response or better to at least one prior line of therapy
- Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status and/or other performance status 0, 1, or 2
- Absolute neutrophil count (ANC) >= 1,000/mm^3 without growth factors within 2 weeks of initiation of treatment
- Platelets >= 75,000/mm^3
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN). In subjects with documents Gilbert’s syndrome, total bilirubin =< 2 x ULN
- Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT)/alkaline phosphatase (ALT) serum glutamic pyruvic transaminase (SGPT) =< 3 x ULN
- Creatinine clearance >= 30 mL/min/1.73 m^2
- Subjects must be willing to give written consent before performance of any study related procedures not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
- Female subjects who: * Are postmenopausal for at least 1 year before the screening visit, OR * Are surgically sterile, OR * If they are of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent form through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
- Male subjects, even if surgically sterilized (i.e., status post-vasectomy), must agree to one of the following: * Agree to practice effective barrier contraception during the entire study treatment period and through 90 days after the last dose of study drug, OR * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
- Subjects who received prior ixazomib at any time or daratumumab or other anti-CD38 therapies, except as part of initial therapy if this was stopped to move on to SCT and the subject did not progress on anti-CD38 treatment
- Subjects are refractory to bortezomib or carfilzomib at the last exposure before this study (defined as subject having PD while receiving bortezomib or carfilzomib therapy or within 60 days after ending bortezomib or carfilzomib therapy)
- Subjects with known allergy to any of the study medications or their analogues
- Subjects planning to undergo SCT prior to PD on this study (i.e., these subjects should not be enrolled in order to reduce disease burden prior to transplant)
- Subjects receiving systemic treatment with strong cytochrome P450, family 3, subfamily A (CYP3A) inducers (e.g. rifampin, rifapentine, rifabutin, carbamazepine, phenytoin, phenobarbital) or use of St. John's wort within 14 days before randomization
- Subjects must have completed their most recent drug therapy directed at multiple myeloma in the following timeframes: * Antitumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy, or investigational agent) within 30 days of study day 1 * Corticosteroids at least 3 weeks prior to starting therapy, except for a dose equivalent to dexamethasone of =< 4 mg/day OR an emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum of 4 days) * Autologous stem cell transplantation at least 12 weeks prior to starting study treatment * Allogeneic stem cell transplantation at least 24 weeks prior to starting treatment, and these subjects must also NOT have moderate to severe active acute or chronic graft versus host disease (GVHD)
- Subjects with known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) < 50% of predicted normal
- Subjects with grade 2 or higher residual toxicities from prior therapy (including grade 2 or higher peripheral neuropathy or any grade neuropathy with pain) with the exception of alopecia
- Subjects who have undergone major surgery within 28 days of study day 1. NOTE: Subjects with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery
- Subjects with central nervous system involvement of myeloma
- Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring intravenous antibiotics or psychiatric illness/social situations that would limit compliance with study requirements
- Subjects with myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association [NYHA] class III and higher), unstable angina, or uncontrolled cardiac arrhythmia (grade 2 or higher)
- Subjects with gastrointestinal (GI) tract disease causing the inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn’s disease, ulcerative colitis)
- Subjects with active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV) positive
- Subjects diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
- Female patients who are lactating or have a positive serum pregnancy test during the screening period
- Radiotherapy within 14 days before enrollment. If the involved field is small, 7 days will be considered a sufficient interval between treatment and administration of the ixazomib
- Participation in other clinical trials, including those with other investigational agents not included in this trial, within 30 days of the start of this trial and throughout the duration of this trial
- Patients that have previously participated in a study with ixazomib whether treated with ixazomib or not
I. To evaluate the progression-free survival of subjects with daratumumab, bortezomib, and dexamethasone (DVd) treatment followed by daratumumab, ixazomib, and dexamethasone (DId) treatment.
I. To evaluate overall response rate (ORR) as assessed by International Myeloma Working Group Criteria (IMWG).
II. To evaluate time to response (TTR).
III. To evaluate time to progression (TTP).
IV. To evaluate duration of response (DOR).
V. To evaluate overall survival (OS).
VI. To evaluate the safety and tolerability.
VII. To evaluate minimal residual disease (MRD) rate.
VIII. To evaluate quality of life (QoL) using the Treatment Satisfaction Questionnaire for Medication (TSMQ-9) and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) patient reported questionnaires.
I. To evaluate biomarkers of response to treatment and mechanisms of resistance with pretreatment and post-treatment bone marrow and blood samples with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing and immune profiling by flow cytometry.
Patients receive daratumumab intravenously (IV) over 3.5-6.5 hours on days 1, 8, and 15, bortezomib subcutaneously (SC) on days 1, 4, 8, and 11, and dexamethasone IV over 15 minutes on days 1, 8, and 15 and orally (PO) on days 2, 4, 5, 9, 11, 12, and 16. Treatment repeats every 28 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive daratumumab IV over 3.5 hours on days 1 and 15 of cycles 4-7 and day 1 of subsequent cycles, ixazomib PO on days 1, 8, and 15, and dexamethasone IV over 15 minutes or PO once weekly. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study, patients are followed up at 30 days and then periodically for up to 24 months.
Trial Phase Phase II
Trial Type Treatment
M D Anderson Cancer Center
Hans Chulhee Lee
- Primary ID 2018-0512
- Secondary IDs NCI-2018-02830
- Clinicaltrials.gov ID NCT03763162